相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity
Carmine Rocca et al.
BIOMEDICINES (2022)
Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy
Ye Chen et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Natural and synthetic antioxidants targeting cardiac oxidative stress and redox signaling in cardiometabolic diseases
Monika Bartekova et al.
FREE RADICAL BIOLOGY AND MEDICINE (2021)
Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy A Randomized Clinical Trial
Lorenzo Livi et al.
JAMA ONCOLOGY (2021)
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies
Alberto Aimo et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
G. Curigliano et al.
ANNALS OF ONCOLOGY (2020)
Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree?
Balaraman Kalyanaraman
REDOX BIOLOGY (2020)
Oxidative Stress and Antioxidant Treatments in Cardiovascular Diseases
Wenjun Wang et al.
ANTIOXIDANTS (2020)
Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring
Nadine Wenningmann et al.
MOLECULAR PHARMACOLOGY (2019)
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity
Monica Samuel Avila et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity
Maryam Nabati et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2017)
Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial
Ahmad Tashakori Beheshti et al.
CARDIOLOGY (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
Drug-induced mitochondrial dysfunction and cardiotoxicity
Zoltan V. Varga et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
The differential effects of green tea on dose-dependent doxorubicin toxicity
Slawomir Mandziuk et al.
FOOD & NUTRITION RESEARCH (2015)
Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
Shiwei Deng et al.
BMC CANCER (2014)
Prevention of Anthracycline-Induced Cardiotoxicity
Pimprapa Vejpongsa et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Doxorubicin-Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy
Filipa S. Carvalho et al.
MEDICINAL RESEARCH REVIEWS (2014)
Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron
Tomáš Šimůnek et al.
Pharmacological Reports (2014)
Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection
Martin Sterba et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang et al.
NATURE MEDICINE (2012)
Myocardial Fatty Acid Metabolism in Health and Disease
Gary D. Lopaschuk et al.
PHYSIOLOGICAL REVIEWS (2010)
Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats
D. Lebrecht et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin
Sergio Gallegos-Castorena et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2007)
New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics
Malgorzata Tokarska-Schlattner et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2006)
Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin
Malgorzata Tokarska-Schlattner et al.
COMPTES RENDUS BIOLOGIES (2006)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin
BB Hasinoff et al.
FREE RADICAL BIOLOGY AND MEDICINE (2003)
分享论文
